Evolution of cellular immune

responses to hepatitis C virus during antiretroviral therapy and its clinical implications Helmut Diepolder, Norbert Gruener Combination antiretroviral therapy (cART) has dramatically decreased the progression to acquired immune deficiency syndrome (AIDS) and thus the human immunodeficiency virus (HIV)-related mortality in HIV-infected patients. Consequently, hepatitis C virus (HCV) has emerged as a leading cause of death in HIV/HCV co-infected patients. Pre-existing HIV infection increases the rate of chronicity in acute HCV infection